O

    OUTLOOK THERAPEUTICS INC (OTLK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.63
    -0.01 (-1.78%)

    Market Cap: $156.50M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -7.37%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    Revenue Consensus
    $-7680170
    Range$-8604170 - $-6756170
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.09 - $-0.01
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.09-80.0%
    60d ago$-0.07-50.0%
    30d ago$-0.07-50.0%
    7d ago$-0.05+0.0%
    Current$-0.05
    Revenue Consensus
    $5M
    Range$1M - $9M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$-0.09$-0.09+0.00%Beat+79.5%
    Mar 26
    		$-0.17$-0.12-41.67%Miss+57.5%
    Dec 25
    		$-0.22$-0.17-29.41%Miss-130.6%
    Sep 25
    		$-0.28$-0.06-366.67%Miss+70.1%
    Jun 25
    		$-0.44$-0.39-12.82%Miss+47.0%
    Mar 25
    		$-0.40$-0.55+27.27%Beat+74.2%
    Dec 24
    		$0.72$-0.62+216.13%Beat+192.3%
    Sep 24
    		$-0.94$-0.90-4.10%Miss-1773.8%
    Jun 24
    		$-0.83$-0.84+1.19%Beat+39.9%
    Mar 24
    		$-1.55$-1.07-44.86%Miss-198.1%
    Dec 23
    		$-0.78$-1.07+27.10%Beat+50.9%
    Sep 23
    		$-0.05$-0.06+16.67%Beat+16.7%
    Jun 23
    		$-1.38$-0.87-58.62%Miss+11.5%
    Mar 23
    		$-0.52N/A+56.67%Beat+70.6%
    Dec 22
    		$-1.59$-1.30-22.31%Miss-1887.5%
    Sep 22
    		$-0.06$-0.07+14.29%Beat+96.3%
    Jun 22
    		$-1.56$-1.33-17.29%Miss-11.4%
    Mar 22
    		$-1.77$-1.20-47.50%Miss+1.7%
    Dec 21
    		$-0.08$-0.06-33.33%Miss+96.4%
    Sep 21
    		$-1.60$-1.27-25.98%Miss-1130.8%
    Jun 21
    		$-1.40$-1.40+0.00%Beat+36.4%
    Mar 21
    		$-1.80$-1.80+0.00%Beat+30.8%
    Dec 20
    		$-2.20$-1.65-33.33%Miss+60.7%
    Sep 20
    		$-0.13$-0.08-62.50%Miss-8.3%
    Jun 20
    		$-2.20$-1.90-15.79%Miss+54.2%
    Mar 20
    		$-2.60$-2.45-6.12%Miss+86.5%
    Dec 19
    		$-5.60$-4.40-27.27%Miss+61.1%
    Sep 19
    		$-0.12N/A+61.29%Beat+62.5%
    Jun 19
    		$-4.80$-7.27+33.98%Beat+85.0%
    Mar 19
    		$-19.26$-13.20-45.91%Miss+62.4%
    Dec 18
    		$-14.40N/A+70.97%Beat-480.6%
    Sep 18
    		$-0.32$-0.23-39.13%Miss+99.1%
    Jun 18
    		$-32.00$-36.80+13.04%Beat+46.1%
    Mar 18
    		$-51.20$-36.80-39.13%Miss+16.4%
    Dec 17
    		$-2.48$-1.92-29.17%Miss+98.1%
    Sep 17
    		$-35.76N/A+63.95%Beat-621.0%
    Jun 17
    		$-59.42$-102.40+41.97%Beat-
    Mar 17
    		$-61.25N/A+59.70%Beat-
    Dec 16
    		$-131.20$-153.60+14.58%Beat-
    Sep 16
    		$-4.96$-4.48-10.71%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.83EV/EBITDA-4.13x
    Price/FCF-0.28xFCF Yield-354.05%
    Profitability
    Profit Margin0.00%Operating Margin-124255.00%
    ROE-3.65%ROIC-769.85%
    Financial Health
    Debt/Equity-1.76xInterest Coverage-2.79x
    Current Ratio0.81xQuick Ratio0.63x
    Trading Statistics
    Beta0.80Avg Volume22.28M
    52-Week High$2.5452-Week Low$0.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.65
    SMA 20$0.81
    SMA 50$1.18
    SMA 200$0.88
    EMA 10$0.68
    EMA 20$0.79
    EMA 50$0.94
    EMA 200$0.95

    MACD

    Line: -0.15Signal: -0.15Hist: -0.00

    ADX

    ADX: 19.7+DI: 19.1-DI: 28.4

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down80.0
    PSAR$0.82

    Bollinger Bands

    Upper Band$1.20
    Lower Band$0.42
    %B Position9712%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K8.4
    Stoch %D8.0
    Williams %R-92.6
    ROC (10d)-5.8%
    Momentum-0.04
    CCI (20d)-66.2
    MFI (14d)10.7

    Volatility Measures

    ATR (14d)$0.11(17.2%)
    StdDev (20d)0.20
    Hist Vol120.6%(High)

    Volume Flow

    VWAP$0.64
    OBV102.1M
    AD Line-247.3M
    CMF (20d)-0.038

    Volume Metrics

    Avg Vol (20d)23.1M
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.77

    Pivot Points

    R3$0.70
    R2$0.68
    R1$0.66
    Pivot Point$0.64
    S1$0.62
    S2$0.60
    S3$0.58

    Advanced Oscillators

    TSI-30.88
    Ultimate Osc32.4
    KST-432.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9,000$127,439$-1,207,833$-91,787$1.51M$0$170,124$170,124$0$0$0$0
    Cost of Revenue$17,000$149,327$29,626$916,515$439,815$29,102$28,801$85,062$28,672$28,195$28,195$11,217
    Gross Profit$-8,000$-21,888$-1,237,459$-1,008,302$1.07M$-29,102$-28,801$85,062$-28,672$-28,195$-28,195$-11,217
    Operating Expenses$10.80M$14.01M$12.25M$16.31M$16.81M$12.39M$21.58M$22.88M$19.56M$18.94M$10.32M$12.46M
    R&D$3.25M$4.50M$3.63M$5.98M$7.13M$4.41M$9.66M$12.52M$11.20M$13.51M$4.53M$4.94M
    SG&A$7.55M$9.50M$8.61M$10.33M$9.68M$7.98M$11.95M$10.35M$8.36M$5.43M$5.79M$7.51M
    Operating Income$-10,810,000$-14,026,987$-13,483,952$-17,314,606$-15,748,680$-12,391,528$-21,606,852$-22,877,000$-19,563,000$-18,940,000$-10,323,000$-12,459,000
    Interest Income$0$0$0$0$0$0$48,881$239,951$404,593$0$0$0
    Interest Expense$9.47M$3.00M$9.57M$264,156$49,351$18,502$0$72.93B$0$3.08M$2142.77B$2142.77B
    Income Before Tax$-20,278,000$-4,453,081$-23,058,135$-14,847,398$-20,152,502$-46,354,406$17.38M$5.69M$44.41M$-114,286,000$-11,178,000$-12,991,000
    Income Tax Expense$41,000$0$0$-1,554,629$0$2,800$17377.60B$0$-2$2,800$-135,335$2.80B
    Net Income$-20,319,000$-4,453,081$-23,058,135$-13,292,769$-20,152,502$-46,357,206$17.38M$5.69M$44.41M$-114,289,000$-11,178,000$-12,991,000
    EBITDA$-20,278,000$-13,996,570$-13,453,878$-14,553,505$-20,073,739$-12,362,426$-21,578,000$5.72M$44.44M$-18,912,000$-10,295,000$-16,742,000
    EBIT$-20,217,509$-14,026,987$-13,483,952$-14,583,242$-20,103,151$-12,391,528$-21,606,801$5.69M$44.41M$-18,940,195$-10,323,195$-16,753,217
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OTLK

    News

    OTLK Should I Buy

    This article provides an analysis of Outlook Therapeutics Inc. (OTLK) for potential investors. It concludes that OTLK is not a good buy due to its current price being significantly below analyst targets, a sharp decline over the past year, and ongoing financial instability including a net loss in Q3 2026. Despite being oversold according to its RSI, negative financial performance and bearish technical indicators suggest caution.

    Intellectia AI•8/22/26•
    Bearish

    Outlook Therapeutics (OTLK) investor held to 9.99% cap

    CVI Investments, Inc. and Heights Capital Management, Inc. reported beneficial ownership of 24,713,908 shares of Outlook Therapeutics (OTLK) common stock, representing 9.9% of the outstanding shares. This includes 20,000,000 common shares and additional shares from warrants, subject to a 9.99% beneficial ownership cap. Heights Capital Management manages the investment for CVI Investments, sharing voting and dispositive power over these shares.

    Stock Titan•8/19/26•
    Neutral

    Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash

    Outlook Therapeutics (OTLK) secured FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD in July 2026, granting 12 years of U.S. regulatory exclusivity, and subsequently raised $51.1 million in an August 2026 equity offering to fund its U.S. commercial launch. Despite this positive development, the company reported an accumulated deficit of $653.5 million and operating losses, leading management to express substantial doubt about its ability to continue as a going concern without further financing. The Q3 2026 financial report detailed a net loss of $47.8 million for the nine months ended June 30, 2026, and limited cash reserves, emphasizing the critical need for additional funding to support operations and commercialization efforts.

    Stock Titan•8/19/26•
    Neutral

    Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus

    US stock futures, led by Nasdaq, rallied premarket due to reports of a US-Iran military pause easing oil price fears. Investors are also focused on a busy week of earnings from major tech companies like Apple, Amazon, Microsoft, and Meta, as well as key economic data including the Fed's rate decision, GDP, and PCE inflation. Retail sentiment remains bearish on SPY and QQQ despite the market rebound.

    Stocktwits•8/19/26•
    Bullish

    Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary

    Outlook Therapeutics, Inc. reported minimal revenue of $8.7K and a net loss of ($20.32M) for the 2026 quarter, with diluted EPS at ($0.15), as it advances commercial launches for its ophthalmology product LYTENAVA. The company has secured regulatory approvals in the US, EU, and UK, and has initiated launches in several European countries while preparing for a US launch. Despite a significant year-over-year decline in revenue, the company is focused on its US launch, broader European rollouts, and exploring licensing opportunities to support commercialization.

    TradingView•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About OTLK

    Does OTLK pay dividends?
    OUTLOOK THERAPEUTICS INC (OTLK) does not currently pay a regular dividend.
    What is OTLK's market cap?
    OUTLOOK THERAPEUTICS INC (OTLK) has a market capitalization of $156.50M with a current stock price of $0.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In